Medical device marketing operates under three conditions that a commercial team cannot negotiate away. Regulation sets a ceiling on what anyone may claim about the product.
Purchasing decisions pass through clinical departments, hospital procurement and network committees rather than a single buyer. Payment depends on a reimbursement decision that the manufacturer does not control. In Belgium, these conditions have specific regulatory and commercial implications that need to be considered before a campaign is developed.
Medical device marketing sits between two better-defined disciplines. Pharmaceutical marketing operates within familiar constraints on marketing prescription drugs to consumers. Health-care services marketing provides an avenue for a clinic to speak freely on the experience of patients. Device companies work with a different mix: regulated products sold to clinical buyers who answer to committees, capital budgets and reimbursement codes. In Belgium, that combination shapes commercial performance more than most creative decisions do.
The claims file sets the ceiling for messaging
Article 7 of the EU Medical Device Regulation prohibits promotional material that misleads users or patients about the intended purpose, safety or performance of a device. It also rules out suggesting uses beyond the intended purpose covered by conformity assessment. The practical consequence is that the technical documentation, rather than the creative brief, determines what a campaign is permitted to say.
A medical device marketing agency that works in this sector usually starts there. It reads the intended purpose statement, the clinical evaluation and the agreed claims before anyone writes a headline. Campaigns that skip that reading tend to stall in regulatory review, and the cost shows up as delay rather than as a rejected invoice.
The Belgian buyer base is concentrated
Belgium organises its general hospitals into locoregional clinical networks. Twenty-three networks were in place in 2025, against a statutory maximum of twenty-five, and each general hospital belongs to one network only. The networks coordinate care assignments across member hospitals, which raises the level at which many purchasing conversations happen. For implants and invasive devices, reimbursement runs through the list maintained by the national health insurance institute, and certain procedures are reimbursed only in hospitals that meet defined criteria.
The commercial effect is that the real audience is a countable set of departments, procurement leads and network committees. Broad awareness spending is poorly matched to a target of that size. A medical device marketing agency that works in Belgium should build segmentation around named accounts and clinical specialties rather than sector-wide impressions.
Language splits the market into separate demand pictures
Belgian law requires device information to reach users in Dutch, French and German, with English accepted for professional users under defined conditions. The requirement often appears in budgets as a translation line item. In practice it behaves more like a segmentation question. A Dutch page rarely ranks for the French terms that a cardiologist in Liège types, and a direct translation seldom matches how clinicians phrase a query. Keyword research therefore runs separately in each language. A medical device marketing agency that handles Belgian demand generation is usually better off treating Flanders and Wallonia as two markets that share one regulator.
Educational material has taken on more of the load
Belgium supervises industry contact with clinicians closely. A device company needs an Mdeon visa before it sponsors a healthcare professional who practises in Belgium to attend a scientific event running over several consecutive calendar days, whether or not the company is based in Belgium. For member companies of beMedTech, the Belgian federation of the medical technology industry, the position is more restrictive: beMedTech members decided internally to stop sponsoring individual participation in scientific events entirely as of January 2022. That internal decision does not change the underlying law, which remains in force for all other device companies, but it is a relevant constraint for any company operating within that federation. Transparency rules require disclosure of benefits granted to professionals and organisations. These rules leave legitimate scientific exchange intact. They do mean that channels once used informally now carry administrative overhead and public visibility.
Educational material carries more of that weight: procedural detail, clinical summaries, health economic arguments and clear comparison against the current standard of care. Clinical and procurement buyers read that material long before they accept a meeting. Output from a medical device marketing agency in this setting often looks closer to technical publishing than to advertising.
Pipeline composition as a measure of progress
Device sales cycles routinely outlast the marketing budget year. Tender timetables, capital cycles and reimbursement decisions set the pace rather than campaign calendars. The
volume of leads would be an inadequate measure of progress. More accurate metrics include: accounts that became active evaluations; meetings where the two groups of stakeholders met for the first time; the proportion of pipeline that originated from owned content; and lead-to-trial placement timeline.
Attribution will stay imperfect. Clean attribution figures deserve scepticism in a market where purchasing decisions sit with committees. For a marketing agency of a medical device, the strong case can be made that marketing helps to make the dialogue shorter and better, and that can be proven through pipeline makeup and not just one conversion rate. Commercial leaders who accept that framing tend to fund marketing consistently. Those who wait for one clean return figure tend to start and stop, and intermittent funding produces little in a market with cycles this long.
Frequently asked questions
1. What makes medical device marketing different from other life sciences marketing?
Claims should align with the use assessed during conformity assessment. End-users are physicians, as well as procurement and network committees. Reimbursement status is what determines adoption, and therefore, there is more value in evidence than storytelling.
2. How does regulatory compliance affect medical device marketing campaigns?
Regulatory compliance defines the ceiling for the claims being made. Article 7 of the Medical Device Regulation does not allow misleading marketing or off-label promotion, thus all marketing claims must be substantiated by evidence.
3. What marketing channels work best for medical device companies?
Search, LinkedIn and specialist clinical media reach device buyers reliably. Owned educational content and congress presence support long evaluations. Channel choice should follow where named accounts already look for evidence.
